¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ  F!omkN  
G.W !   
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© .|UQ)J?s  
hx;f/E Px  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© V>Wk\'h  
$NXP)Lic)  
1.Co-stimulators (or co-stimulating molecules) Swi# ^i  
"LMj,qZ1!  
2.NK-kB ZO0 Ee1/  
?^}30V:E  
3.Immunoglobulin superfamily %bW_,b  
2eT?qCxqc  
4.antigen-presenting cell (APC) 'D\Q$q  
(i1JRn- f  
5.death domain jlEz]@ i  
7s9h:/Lu  
6.CCR and CXCR Vz{+3vfra6  
d=!:UB  
7.Lectin (or mitogen) +6m.f,14q  
N.F5)04  
8.Clusters of differentiation, CD) 7R+(3NU1A  
G#M)5'Q]U  
9.B7 family !40>LpL[  
nB[-KS  
10.Cytotoxic T lymphocyte, CTL) k9|5TLXq?  
jN=<d q ~  
11.IL-15 and IL-15 receptor (IL-15R) tYS4"Nfb+  
+n3I\7G>  
12.MHC restriction W :w~ M'o  
rr<E#w  
13.Affinity-chromatography bp1AN9~  
8xpplo8  
14.Cyctosprin A, CsA "tK%]c d-  
9 _d2u#  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) *Ak.KBg  
md!6@)S-p  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© ;"3B,Yj  
s6H'}[E<  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 |(7}0]BP0  
_n&Nw7d2 M  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ! >UlvT-  
$YYWpeW '  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ _IH" SVub  
?J[3_!"t  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© }5o?7} ?  
;*K4{wvG  
ÃâÒßѧרҵ£º MB plhVK8  
1MelHW  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ >rG>Bz^Pu  
9&Y@g)+2  
Ïû»¯ÄÚ¿Æ£º :yay:3qv  
Fu7:4+  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 5*0zI\  
[^H2'& ]  
ѪҺ²¡Ñ§×¨Òµ£º  Et>#&Nw8  
)7q$Pc Y  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»